Carolyn E. Taylor

Director Carolyn E. Taylor bought 1,415 shares of TNXP at $10.55; stock down -83.8% from 52-week high, insider's prior TNXP trade lost -53.6% over 90 days.

Carolyn E. Taylor purchased 1,415 shares at $10.55 on 2026-06-12, expanding her position by 338.5%, but the timing reflects a difficult market backdrop: the current price of $11.35 is -83.8% below the 52-week high of $69.97, and Taylor's prior open-market buy at TNXP on 2025-08-21 delivered a -53.6% return over 90 days. The stock has declined -18.0% in the past 30 days and -14.3% over 90 days, placing this purchase in a downtrend. Fundamentally, the company reported $-40,194,000.00 in net income last quarter and was unprofitable over its most recent full fiscal year, though annual revenue grew 29.8% year-over-year. The purchase occurs alongside cluster buying activity (2 other insiders bought within the past 14 days), which may indicate coordinated conviction or may simply reflect coincidental trading windows, but the pattern of losses on Taylor's prior trade at this ticker and the company's cash-burn trajectory suggest elevated caution is warranted.

Director Taylor Carolyn E. purchased 418 shares of TNXP at $36.03 (initial stake); stock now -41.8% from 52-week high despite +29.9% annual revenue growth.

Taylor Carolyn E., a director, acquired 418 shares of Tonix Pharmaceuticals at $36.03 per share on August 21, 2025, representing an initial holding position in the company. The purchase occurred at a significant premium to the current price of $35.85 and well above the 52-week low of $7.38, but the stock remains substantially depressed at -41.8% below its 52-week high of $61.57. Against a backdrop of strong revenue growth of +29.9% year-over-year, the company reported a net loss of $-28.3M in its most recent full fiscal year, indicating ongoing profitability challenges that may weigh on near-term investor sentiment. The combination of an insider director's initiation of a position alongside elevated cash burn and a sharply pullback price warrants investor monitoring of both the company's path to profitability and any material operational developments.